50. Dermatomyositis
157 clinical trials,   207 drugs   (DrugBank: 76 drugs),   47 drug target genes,   142 drug target pathways

Searched query = "Dermatomyositis", "Polymyositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs031200005
30/04/202010/04/2020Investigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositisInvestigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositis - ACDM Dermatomyositis
Collagen disease, inflammatory myopathy, cutaneous manifestation;D003882
Oral administration of apremilast: Start with 10 mg of oral dose and gradually increase the dose until day 5, 30mg twice a day from day 6 (morning / evening) for a total of 12 weeksOkiyama NaokoNULLNot Recruiting>= 20age old< 80age oldBoth5Japan
2NCT03529955
(ClinicalTrials.gov)
June 12, 201824/4/2018Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant DermatomyositisA Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant DermatomyositisDermatomyositis, Adult TypeDrug: Apremilast 30mgTulane UniversityNULLRecruiting18 Years75 YearsAll10Phase 2United States
3NCT01140503
(ClinicalTrials.gov)
February 20106/4/2010A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With DermatomyositisAn Open Label Study Evaluating the Safety and Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With DermatomyositisDermatomyositisDrug: ApremilastStanford UniversityNULLTerminated18 YearsN/AAll5N/AUnited States